Volume | 4,198,930 |
|
|||||
News | - | ||||||
Day High | 2.01 | Low High |
|||||
Day Low | 1.88 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Esperion Therapeutics Inc | ESPR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
2.01 | 1.88 | 2.01 | 1.90 | 1.99 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
10,592 | 4,198,930 | US$ 1.93 | US$ 8,098,230 | - | 0.70 - 3.40 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:58:55 | 55 | US$ 1.89 | USD |
Esperion Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
349.75M | 185.05M | - | 116.33M | -209.25M | -1.13 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Esperion Therapeutics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ESPR Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.78 | 2.16 | 1.71 | 2.01 | 5,515,336 | 0.12 | 6.74% |
1 Month | 2.70 | 3.40 | 1.71 | 2.55 | 7,676,784 | -0.80 | -29.63% |
3 Months | 2.09 | 3.40 | 1.71 | 2.51 | 6,379,320 | -0.19 | -9.09% |
6 Months | 0.78 | 3.40 | 0.706 | 2.25 | 6,019,012 | 1.12 | 143.59% |
1 Year | 1.22 | 3.40 | 0.70 | 1.93 | 4,590,209 | 0.68 | 55.74% |
3 Years | 27.59 | 28.75 | 0.70 | 3.82 | 2,644,734 | -25.69 | -93.11% |
5 Years | 43.86 | 79.989 | 0.70 | 8.73 | 1,829,417 | -41.96 | -95.67% |
Esperion Therapeutics Description
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. |